Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2016-08-19 Interim / Quarterly Rep…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report 9M 2016
2016-08-19 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to shareholder meetings. It includes a letter from the Chairman discussing company strategy, board changes, and an invitation to the annual meeting. The document is not a full annual report, earnings release, or financial report but rather materials sent to shareholders to provide information and request votes for meetings. The presence of the SEC header, the title 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934', and the content focused on shareholder meeting information and board changes confirm this classification. Therefore, the document fits the Proxy Solicitation & Information Statement category (PSI). The document length (8058 characters) and content confirm it is not a mere announcement but actual proxy materials.
2016-07-05 English
DEF 14A
Proxy Solicitation & Information Statement
2016-07-05 English
PRIMARY DOCUMENT
Director's Dealing
2016-07-05 English
PRIMARY DOCUMENT
Director's Dealing
2016-06-29 English
PRIMARY DOCUMENT
Director's Dealing
2016-06-20 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.